Journal Home > Volume 10 , Issue 3
Journal of Neurorestoratology 2022, 10(3): 100015 https://doi.org/10.1016/j.jnrt.2022.100015
Practice Guidelines | Open Access | Issue | Published: 30 July 2022

Clinical cell therapy guidelines for neurorestoration (IANR/CANR 2022)☆

Show Author's Information Hongyun Huanga( ),  Ziad M. Al Zoubib,  Gustavo Movigliac,  Hari Shanker Sharmad,  Anna Sarnowskae,  Paul R. Sanbergf,  Lin Cheng,  Qun Xueh,  Dario Siniscalcoi,  Shiqing Fengj,  Hooshang Saberik,  Xiaoling Guol,  Mengzhou Xuem,  Milan R. Dimitrijevicn,  Russell J. Andrewso,  Gengsheng Maop,  Robert Chunhua Zhaoq,  Fabin Hanr
Beijing Hongtianji Neuroscience Academy, Beijing 100143, China
Jordan Ortho and Spinal Centre, Al-Saif Medical Center, Amman, Jordan
Wake Forest Institute for Regenerative Medicine of Wake Forest University, North Carolina, USA
Intensive Experimental CNS Injury and Repair, University Hospital, Uppsala University, Uppsala, Sweden
Translational Platform for Regenerative Medicine, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland
Center of Excellence for Aging & Brain Repair, Department of Neurosurgery & Brain Repair, Morsani College of Medicine, University of South Florida, Tampa 33612, Florida, USA
Department of Neurosurgery, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100700, China
Department of Neurology, First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu, China
Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
Department of Orthopaedics, Tianjin Medical University General Hospital, Tianjin 300052, China
Department of Neurosurgery, Brain and Spinal Injury Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
Neurological Department, 981 Hospital of Chinese PLA, Chengde 067000, Hebei, China
Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450001, Henan, China
Baylor College of Medicine, Houston, TX, USA
World Federation of Neurosurgical Societies, Nyon, Switzerland
Department of Neurosurgery, Third Medical Center of General Hospital of PLA, Beijing 100039, China
Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Center of Excellence in Tissue Engineering, Chinese Academy of Medical Sciences, Beijing 100005, China
The Institute for Tissue Engineering and Regenerative Medicine, Stem Cell and Regenerative Medicine Laboratory, Liaocheng University / Liaocheng People's Hospital, Liaocheng 252000, Shandong, China
Keywords:
Cell therapy, Neurorestoration, Neurorestoratology, Clinical application guideline
Cite this article:
Huang H, Al Zoubi ZM, Moviglia G, et al. Clinical cell therapy guidelines for neurorestoration (IANR/CANR 2022)☆. Journal of Neurorestoratology, 2022, 10(3): 100015. https://doi.org/10.1016/j.jnrt.2022.100015
Download citation
EndNote(RIS)
BibTeX

608

Views

59

Downloads

Citations

6

Crossref

5

WoS

0

Scopus

N/A

CSCD

Abstract Full text About this article

Cell therapy has been shown to be a crucial clinical therapeutic option for central nervous system diseases or damage. Promoting standardization of clinical cell therapy procedures is essential for professional associations devoted to cell therapy. The International Association of Neurorestoratology (IANR) and the Chinese Association of Neurorestoratology (CANR; Preparatory) collaborated to release Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017) in 2018. Due to recent advances and achievements in clinical cell therapy worldwide in recent years, IANR and CANR have renewed and updated the guidelines. Except for the requirements of equipment, personnel, and ethics, these revised guidelines include cell type nomenclature, cell quality control, cell types in clinical application, minimal suggested cellular doses, patient-informed consent, indications and contraindications for undergoing cell therapy, documentation of procedure and therapy, safety evaluation, efficacy evaluation, the policy of repeated treatments, do not charge patients for unproven therapies, basic principles of cell therapy, and publishing responsibility. IANR/CANR recommends that all clinical practitioners follow these cellular therapy guidelines. These guidelines provide references of better cell types, doses, routes, and therapeutic timing windows in different diseases.


menu
Abstract
Full text
Outline
About this article

Clinical cell therapy guidelines for neurorestoration (IANR/CANR 2022)☆

Show Author's information Hongyun Huanga( ), Ziad M. Al Zoubib, Gustavo Movigliac, Hari Shanker Sharmad, Anna Sarnowskae, Paul R. Sanbergf, Lin Cheng, Qun Xueh, Dario Siniscalcoi, Shiqing Fengj, Hooshang Saberik, Xiaoling Guol, Mengzhou Xuem, Milan R. Dimitrijevicn, Russell J. Andrewso, Gengsheng Maop, Robert Chunhua Zhaoq, Fabin Hanr
Beijing Hongtianji Neuroscience Academy, Beijing 100143, China
Jordan Ortho and Spinal Centre, Al-Saif Medical Center, Amman, Jordan
Wake Forest Institute for Regenerative Medicine of Wake Forest University, North Carolina, USA
Intensive Experimental CNS Injury and Repair, University Hospital, Uppsala University, Uppsala, Sweden
Translational Platform for Regenerative Medicine, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland
Center of Excellence for Aging & Brain Repair, Department of Neurosurgery & Brain Repair, Morsani College of Medicine, University of South Florida, Tampa 33612, Florida, USA
Department of Neurosurgery, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100700, China
Department of Neurology, First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu, China
Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
Department of Orthopaedics, Tianjin Medical University General Hospital, Tianjin 300052, China
Department of Neurosurgery, Brain and Spinal Injury Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
Neurological Department, 981 Hospital of Chinese PLA, Chengde 067000, Hebei, China
Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450001, Henan, China
Baylor College of Medicine, Houston, TX, USA
World Federation of Neurosurgical Societies, Nyon, Switzerland
Department of Neurosurgery, Third Medical Center of General Hospital of PLA, Beijing 100039, China
Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Center of Excellence in Tissue Engineering, Chinese Academy of Medical Sciences, Beijing 100005, China
The Institute for Tissue Engineering and Regenerative Medicine, Stem Cell and Regenerative Medicine Laboratory, Liaocheng University / Liaocheng People's Hospital, Liaocheng 252000, Shandong, China

Abstract

Cell therapy has been shown to be a crucial clinical therapeutic option for central nervous system diseases or damage. Promoting standardization of clinical cell therapy procedures is essential for professional associations devoted to cell therapy. The International Association of Neurorestoratology (IANR) and the Chinese Association of Neurorestoratology (CANR; Preparatory) collaborated to release Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017) in 2018. Due to recent advances and achievements in clinical cell therapy worldwide in recent years, IANR and CANR have renewed and updated the guidelines. Except for the requirements of equipment, personnel, and ethics, these revised guidelines include cell type nomenclature, cell quality control, cell types in clinical application, minimal suggested cellular doses, patient-informed consent, indications and contraindications for undergoing cell therapy, documentation of procedure and therapy, safety evaluation, efficacy evaluation, the policy of repeated treatments, do not charge patients for unproven therapies, basic principles of cell therapy, and publishing responsibility. IANR/CANR recommends that all clinical practitioners follow these cellular therapy guidelines. These guidelines provide references of better cell types, doses, routes, and therapeutic timing windows in different diseases.

Keywords: Cell therapy, Neurorestoration, Neurorestoratology, Clinical application guideline

References(144)

[1]

Huang HY, Young W, Chen L, et al. Clinical cell therapy guidelines for neurorestoration (IANR/CANR 2017). Cell Transplant. 2018;27(2): 310-324.
DOI Google Scholar
[2]

Wang YL, Guo XL, Liu YQ, et al. A pilot study of clinical cell therapy for patients with vascular dementia. J Neurorestoratol. 2021;9(2): 137-150.
DOI Google Scholar
[3]

Wang YL, Guo XL, Liu J, et al. Olfactory ensheathing cells in chronic ischemic stroke: a phase 2, double-blind, randomized, controlled trial. J Neurorestoratol. 2020;8(3): 182-193.
DOI Google Scholar
[4]

Guo XL, Wang X, Li Y, et al. Olfactory ensheathing cell transplantation improving cerebral infarction sequela: a case report and literature review. J Neurorestoratol. 2019;7(2): 82-88.
DOI Google Scholar
[5]

Kuang NF, Wang XY, Chen YX, et al. Olfactory ensheathing cell transplantation for chronic spinal cord injury: a long-term follow-up study. J Neurorestoratol. 2021;9(2): 94-105.
DOI Google Scholar
[6]

Cheng ZJ, Wang R, Cao K, et al. Ten years of clinical observation of olfactory ensheathing cell transplantation in patients with spinal cord injury. J Neurorestoratol. 2021;9(2): 106-116.
DOI Google Scholar
[7]

Hammadi AMA, Alhimyari F. Intra-arterial injection of autologous bone marrow-derived mononuclear cells in ischemic stroke patients. Exp Clin Transplant. 2019;17(suppl 1): 239-241.
DOI Google Scholar
[8]

Haque ME, Gabr RE, George SD, et al. Serial cerebral metabolic changes in patients with ischemic stroke treated with autologous bone marrow derived mononuclear cells. Front Neurol. 2019;10: 141.
DOI Google Scholar
[9]

Liem NT, Chinh VD, Thinh NT, et al. Improved bowel function in patients with spina bifida after bone marrow-derived mononuclear cell transplantation: a report of 2 cases. Am J Case Rep. 2018;19: 1010-1018.
DOI Google Scholar
[10]

Liem NT, Huyen TL, Huong LT, et al. Outcomes of bone marrow mononuclear cell transplantation for neurological sequelae due to intracranial hemorrhage incidence in the neonatal period: report of four cases. Front Pediatr. 2019;7: 543.
DOI Google Scholar
[11]

Liem NT, Chinh VD, Phuong DTM, et al. Outcomes of bone marrow-derived mononuclear cell transplantation for patients in persistent vegetative state after drowning: report of five cases. Front Pediatr. 2020;8: 564.
DOI Google Scholar
[12]

Cox Jr CS, Hetz RA, Liao GP, et al. Treatment of severe adult traumatic brain injury using bone marrow mononuclear cells. Stem Cell. 2017;35(4): 1065-1079.
DOI Google Scholar
[13]

Bhasin A, Kumaran SS, Bhatia R, et al. Safety and feasibility of autologous mesenchymal stem cell transplantation in chronic stroke in Indian patients. A four-year follow up. J Stem Cells Regen Med. 2017;13(1): 14-19.
DOI Google Scholar
[14]

Laskowitz DT, Bennett ER, Durham RJ, et al. Allogeneic umbilical cord blood infusion for adults with ischemic stroke: clinical outcomes from a phase Ⅰ safety study. Stem Cells Transl Med. 2018;7(7): 521-529.
DOI Google Scholar
[15]

Bhatia V, Gupta V, Khurana D, et al. Randomized assessment of the safety and efficacy of intra-arterial infusion of autologous stem cells in subacute ischemic stroke. AJNR Am J Neuroradiol. 2018;39(5): 899-904.
DOI Google Scholar
[16]

Sharma A, Sane H, Gokulchandran N, et al. An open-label proof-of-concept study of intrathecal autologous bone marrow mononuclear cell transplantation in intellectual disability. Stem Cell Res Ther. 2018;9(1): 19.
DOI Google Scholar
[17]

Sharma A, Sane H, Gokulchandran N, et al. Intrathecal transplantation of autologous bone marrow mononuclear cells in patients with sub-acute and chronic spinal cord injury: an open-label study. Int J Health Sci. 2020;14(2): 24-32.
Google Scholar
[18]

Sharma AK, Sane HM, Kulkarni PP, et al. Autologous bone marrow mononuclear cell transplantation in patients with chronic traumatic brain injury- a clinical study. Cell Regen. 2020;9(1): 3.
DOI Google Scholar
[19]

Sharma A, Sane H, Paranjape A, et al. Improved survival in amyotrophic lateral sclerosis patients following autologous bone marrow mononuclear cell therapy: a long term 10-year retrospective study. J Neurorestoratol. 2021;9(2): 117-136.
DOI Google Scholar
[20]

Nguyen LT, Nguyen AT, Vu CD, et al. Outcomes of autologous bone marrow mononuclear cells for cerebral palsy: an open label uncontrolled clinical trial. BMC Pediatr. 2017;17(1): 104.
DOI Google Scholar
[21]

Nguyen TL, Nguyen HP, Nguyen TK. The effects of bone marrow mononuclear cell transplantation on the quality of life of children with cerebral palsy. Health Qual Life Outcome. 2018;16(1): 164.
DOI Google Scholar
[22]

Nguyen Thanh L, Nguyen HP, Ngo MD, et al. Outcomes of bone marrow mononuclear cell transplantation combined with interventional education for autism spectrum disorder. Stem Cells Transl Med. 2021;10(1): 14-26.
DOI Google Scholar
[23]

Chernykh E, Shevela E, Kafanova M, et al. Monocyte-derived macrophages for treatment of cerebral palsy: a study of 57 cases. J Neurorestoratol. 2018;6: 41-47.
DOI Google Scholar
[24]

Srivastava RN, Agrahari AK, Singh A, et al. Effectiveness of bone marrowderived mononuclear stem cells for neurological recovery in participants with spinal cord injury: a randomized controlled trial. Asian J Transfus Sci. 2019;13(2): 120-128.
DOI Google Scholar
[25]

Derakhshanrad N, Saberi H, Yekaninejad MS, et al. Subcutaneous granulocyte colony-stimulating factor administration for subacute traumatic spinal cord injuries, report of neurological and functional outcomes: a double-blind randomized controlled clinical trial. J Neurosurg Spine. 2018;30(1): 19-30.
DOI Google Scholar
[26]

Derakhshanrad N, Saberi H, Yekaninejad MS, et al. Granulocyte-colony stimulating factor administration for neurological improvement in patients with postrehabilitation chronic incomplete traumatic spinal cord injuries: a double-blind randomized controlled clinical trial. J Neurosurg Spine. 2018;29(1): 97-107.
DOI Google Scholar
[27]

Syková E, Rychmach P, Drahorádová I, et al. Transplantation of mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: results of phase Ⅰ/Ⅱa clinical trial. Cell Transplant. 2017;26(4): 647-658.
DOI Google Scholar
[28]

Tsang KS, Ng CPS, Zhu XL, et al. Phase Ⅰ/Ⅱ randomized controlled trial of autologous bone marrow-derived mesenchymal stem cell therapy for chronic stroke. World J Stem Cell. 2017;9(8): 133-143.
DOI Google Scholar
[29]

Levy ML, Crawford JR, Dib N, et al. Phase Ⅰ/Ⅱ study of safety and preliminary efficacy of intravenous allogeneic mesenchymal stem cells in chronic stroke. Stroke. 2019;50(10): 2835-2841.
DOI Google Scholar
[30]

Brunet MC, Chen SH, Khandelwal P, et al. Intravenous stem cell therapy for high-grade aneurysmal subarachnoid hemorrhage: case report and literature review. World Neurosurg. 2019;128: 573-575.
DOI Google Scholar
[31]

Ahn H, Lee SY, Jung WJ, et al. Treatment of acute ischemic stroke by minimally manipulated umbilical cord-derived mesenchymal stem cells transplantation: a case report. World J Stem Cell. 2021;13(8): 1151-1159.
DOI Google Scholar
[32]

Larocca TF, Macêdo CT, Souza B, et al. Image-guided percutaneous intrale-sional administration of mesenchymal stromal cells in subjects with chronic complete spinal cord injury: a pilot study. Cytotherapy. 2017;19(10): 1189-1196.
DOI Google Scholar
[33]

Guadalajara Labajo H, León Arellano M, Vaquero Crespo J, et al. Objective demonstration of improvement of neurogenic bowel dysfunction in a case of spinal cord injury following stem cell therapy. J Surg Case Rep. 2018;2018(11): rjy300.
DOI Google Scholar
[34]

Santamaría AJ, Benavides FD, DiFede DL, et al. Clinical and neurophysiological changes after targeted intrathecal injections of bone marrow stem cells in a C3 tetraplegic subject. J Neurotrauma. 2019;36(3): 500-516.
DOI Google Scholar
[35]

Vaquero J, Zurita M, Rico MA, et al. Repeated subarachnoid administrations of autologous mesenchymal stromal cells supported in autologous plasma improve quality of life in patients suffering incomplete spinal cord injury. Cytotherapy. 2017;19(3): 349-359.
DOI Google Scholar
[36]

Vaquero J, Zurita M, Bonilla C, et al. Progressive increase in brain glucose metabolism after intrathecal administration of autologous mesenchymal stromal cells in patients with diffuse axonal injury. Cytotherapy. 2017;19(1): 88-94.
DOI Google Scholar
[37]

Vaquero J, Zurita M, Rico MA, et al. Intrathecal administration of autologous bone marrow stromal cells improves neuropathic pain in patients with spinal cord injury. Neurosci Lett. 2018;670: 14-18.
DOI Google Scholar
[38]

Vaquero J, Zurita M, Rico MA, et al. Intrathecal administration of autologous mesenchymal stromal cells for spinal cord injury: safety and efficacy of the 100/3 guideline. Cytotherapy. 2018;20(6): 806-819.
DOI Google Scholar
[39]

Vaquero J, Zurita M, Rico MA, et al. Cell therapy with autologous mesenchymal stromal cells in post-traumatic syringomyelia. Cytotherapy. 2018;20(6): 796-805.
DOI Google Scholar
[40]

Vaquero J, Zurita M, Mucientes J, et al. Intrathecal cell therapy with autologous stromal cells increases cerebral glucose metabolism and can offer a new approach to the treatment of Alzheimer's type dementia. Cytotherapy. 2019;21(4): 428-432.
DOI Google Scholar
[41]

Bydon M, Dietz AB, Goncalves S, et al. CELLTOP clinical trial: first report from a phase 1 trial of autologous adipose tissue-derived mesenchymal stem cells in the treatment of paralysis due to traumatic spinal cord injury. Mayo Clin Proc. 2020;95(2): 406-414.
DOI Google Scholar
[42]

Phedy P, Djaja YP, Gatam L, et al. Motoric recovery after transplantation of bone marrow derived mesenchymal stem cells in chronic spinal cord injury: a case report. Am J Case Rep. 2019;20: 1299-1304.
DOI Google Scholar
[43]

Yang Y, Pang M, Du C, et al. Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: a phase 1/2 pilot study. Cytotherapy. 2021;23(1): 57-64.
DOI Google Scholar
[44]

Huang L, Zhang C, Gu JW, et al. A randomized, placebo-controlled trial of human umbilical cord blood mesenchymal stem cell infusion for children with cerebral palsy. Cell Transplant. 2018;27(2): 325-334.
DOI Google Scholar
[45]

Boruczkowski D, Zdolińska-Malinowska I. Wharton's jelly mesenchymal stem cell administration improves quality of life and self-sufficiency in children with cerebral palsy: results from a retrospective study. Stem Cell Int. 2019;2019, 7402151.
DOI Google Scholar
[46]

Boruczkowski D, Zdolińska-Malinowska I. A retrospective analysis of safety and efficacy of wharton's jelly stem cell administration in children with spina bifida. Stem Cell Rev Rep. 2019;15(5): 717-729.
DOI Google Scholar
[47]

Kabataş S, Civelek E, Kaplan N, et al. Phase Ⅰ study on the safety and preliminary efficacy of allogeneic mesenchymal stem cells in hypoxic-ischemic encephalopathy. World J Exp Med. 2021;11(2): 17-29.
DOI Google Scholar
[48]

Kabatas S, Civelek E, Savrunlu EC, et al. Feasibility of allogeneic mesenchymal stem cells in pediatric hypoxic-ischemic encephalopathy: phase Ⅰ study. World J Stem Cell. 2021;13(5): 470-484.
DOI Google Scholar
[49]

Riordan NH, Hincapié ML, Morales I, et al. Allogeneic human umbilical cord mesenchymal stem cells for the treatment of autism spectrum disorder in children: safety profile and effect on cytokine levels. Stem Cells Transl Med. 2019;8(10): 1008-1016.
DOI Google Scholar
[50]

Pan K, Deng LN, Chen PY, et al. Safety and feasibility of repeated intrathecal allogeneic bone marrow-derived mesenchymal stromal cells in patients with neurological diseases. Stem Cell Int. 2019;2019: 8421281.
DOI Google Scholar
[51]

Numan MT, Kamdar A, Young J, et al. Autologous adipose stem cell therapy for autonomic nervous system dysfunction in two young patients. Stem Cell Dev. 2017;26(6): 391-393.
DOI Google Scholar
[52]

Albu S, Kumru H, Coll R, et al. Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study. Cytotherapy. 2021;23(2): 146-156.
DOI Google Scholar
[53]

Zhao TT, Liang QL, Meng XH, et al. Intravenous infusion of umbilical cord mesenchymal stem cells maintains and partially improves visual function in patients with advanced retinitis pigmentosa. Stem Cell Dev. 2020;29(16): 1029-1037.
DOI Google Scholar
[54]

Tuekprakhon A, Sangkitporn S, Trinavarat A, et al. Intravitreal autologous mesenchymal stem cell transplantation: a non-randomized phase Ⅰ clinical trial in patients with retinitis pigmentosa. Stem Cell Res Ther. 2021;12(1): 52.
DOI Google Scholar
[55]

Tsai YA, Liu RS, Lirng JF, et al. Treatment of spinocerebellar Ataxia with mesenchymal stem cells: a phase Ⅰ/Ⅱa clinical study. Cell Transplant. 2017;26(3): 503-512.
DOI Google Scholar
[56]

Oh KW, Noh MY, Kwon MS, et al. Repeated intrathecal mesenchymal stem cells for amyotrophic lateral sclerosis. Ann Neurol. 2018;84(3): 361-373.
DOI Google Scholar
[57]

Barczewska M, Maksymowicz S, Zdolińska-Malinowska I, et al. Umbilical cord mesenchymal stem cells in amyotrophic lateral sclerosis: an original study. Stem Cell Rev Rep. 2020;16(5): 922-932.
DOI Google Scholar
[58]

Petrou P, Kassis I, Yaghmour NE, et al. A phase Ⅱ clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis. Front Biosci (Landmark Ed). 2021;26(10): 693-706.
DOI Google Scholar
[59]

Kobinia GS, Zaknun JJ, Pabinger C, et al. Case report: autologous bone marrow derived intrathecal stem cell transplant for autistic children - a report of four cases and literature review. Front Pediatr. 2021;9: 620188.
DOI Google Scholar
[60]

Sharifzadeh N, Ghasemi A, Tavakol Afshari J, et al. Intrathecal autologous bone marrow stem cell therapy in children with autism: a randomized controlled trial. Asia Pac Psychiatr. 2021;13(2), e12445.
DOI Google Scholar
[61]

Honmou O, Yamashita T, Morita T, et al. Intravenous infusion of auto serumexpanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series. Clin Neurol Neurosurg. 2021;203: 106565.
DOI Google Scholar
[62]

Anderson KD, Guest JD, Dietrich WD, et al. Safety of autologous human schwann cell transplantation in subacute thoracic spinal cord injury. J Neurotrauma. 2017;34(21): 2950-2963.
DOI Google Scholar
[63]

Santamaria AJ, Benavides FD, Saraiva PM, et al. Neurophysiological changes in the first year after cell transplantation in sub-acute complete paraplegia. Front Neurol. 2020;11: 514181.
DOI Google Scholar
[64]

Gant KL, Guest JD, Palermo AE, et al. Phase 1 safety trial of autologous human schwann cell transplantation in chronic spinal cord injury. J Neurotrauma. 2022;39(3/4): 285-299.
DOI Google Scholar
[65]

Goutman SA, Brown MB, Glass JD, et al. Long-term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS. Ann Clin Transl Neurol. 2018;5(6): 730-740.
DOI Google Scholar
[66]

Liu Y, Chen SJ, Li SY, et al. Long-term safety of human retinal progenitor cell transplantation in retinitis pigmentosa patients. Stem Cell Res Ther. 2017;8(1): 209.
DOI Google Scholar
[67]

Chen WG, Zhang Y, Yang SZ, et al. NeuroRegen scaffolds combined with autologous bone marrow mononuclear cells for the repair of acute complete spinal cord injury: a 3-year clinical study. Cell Transplant. 2020;29, 096368972095063.
DOI Google Scholar
[68]

Oraee-Yazdani S, Akhlaghpasand M, Golmohammadi M, et al. Combining cell therapy with human autologous Schwann cell and bone marrow-derived mesenchymal stem cell in patients with subacute complete spinal cord injury: safety considerations and possible outcomes. Stem Cell Res Ther. 2021;12(1): 445.
DOI Google Scholar
[69]

Zamani H, Soufizomorrod M, Oraee-Yazdani S, et al. Safety and feasibility of autologous olfactory ensheathing cell and bone marrow mesenchymal stem cell co-transplantation in chronic human spinal cord injury: a clinical trial. Spinal Cord. 2022;60(1): 63-70.
DOI Google Scholar
[70]

Zhao YN, Tang FW, Xiao ZF, et al. Clinical study of NeuroRegen scaffold combined with human mesenchymal stem cells for the repair of chronic complete spinal cord injury. Cell Transplant. 2017;26(5): 891-900.
DOI Google Scholar
[71]

Xiao ZF, Tang FW, Zhao YN, et al. Significant improvement of acute complete spinal cord injury patients diagnosed by a combined criteria implanted with NeuroRegen scaffolds and mesenchymal stem cells. Cell Transplant. 2018;27(6): 907-915.
DOI Google Scholar
[72]

Tang F, Tang J, Zhao Y, et al. Long-term clinical observation of patients with acute and chronic complete spinal cord injury after transplantation of NeuroRegen scaffold. Sci China Life Sci. 2022;65(5): 909-926.
DOI Google Scholar
[73]

Liu XB, Fu XJ, Dai GH, et al. Comparative analysis of curative effect of bone marrow mesenchymal stem cell and bone marrow mononuclear cell transplantation for spastic cerebral palsy. J Transl Med. 2017;15(1): 48.
DOI Google Scholar
[74]

Moviglia GA, Moviglia Brandolino MT, Couto D, et al. Local immunomodulation and muscle progenitor cells induce recovery in atrophied muscles in spinal cord injury patients. J Neurorestoratol. 2018;6(1): 136-145.
DOI Google Scholar
[75]

van Horne CG, Quintero JE, Slevin JT, et al. Peripheral nerve grafts implanted into the substantia nigra in patients with Parkinson's disease during deep brain stimulation surgery: 1-year follow-up study of safety, feasibility, and clinical outcome. J Neurosurg. 2018;129(6): 1550-1561.
DOI Google Scholar
[76]

Frau J, Carai M, Coghe G, et al. Long-term follow-up more than 10 years after HSCT: a monocentric experience. J Neurol. 2018;265(2): 410-416.
DOI Google Scholar
[77]

Moore JJ, Massey JC, Ford CD, et al. Prospective phase Ⅱ clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(5): 514-521.
DOI Google Scholar
[78]

Casanova B, Jarque I, Gascón F, et al. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. Neurol Sci. 2017;38(7): 1213-1221.
DOI Google Scholar
[79]

Muraro PA, Pasquini M, Atkins HL, et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol. 2017;74(4): 459-469.
DOI Google Scholar
[80]

Burt RK, Balabanov R, Burman J, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA. 2019;321(2): 165-174.
DOI Google Scholar
[81]

Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology. 2017;88(9): 842-852.
DOI Google Scholar
[82]

Sung PH, Lin HS, Lin WC, et al. Intra-carotid arterial transfusion of autologous circulatory derived CD34+ cells for old ischemic stroke patients - a phase Ⅰ clinical trial to evaluate safety and tolerability. Am J Transl Res. 2018;10(9): 2975-2989.
Google Scholar
[83]

Chen Y, Zhang XH, Xu LP, et al. Haploidentical allogenetic hematopoietic stem cell transplantation for X-linked adrenoleukodystrophy (in Chinese). Beijing Da Xue Xue Bao Yi Xue Ban. 2019;51(3): 409-413.
Google Scholar
[84]

Goudie C, Alayoubi AM, Tibout P, et al. Hematopoietic stem cell transplant does not prevent neurological deterioration in infants with Farber disease: case report and literature review. JIMD Rep. 2019;46(1): 46-51.
DOI Google Scholar
[85]

da Cruz L, Fynes K, Georgiadis O, et al. Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration. Nat Biotechnol. 2018;36(4): 328-337.
DOI Google Scholar
[86]

Kashani AH, Lebkowski JS, Rahhal FM, et al. A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration. Sci Transl Med. 2018;10(435). eaao4097.
DOI Google Scholar
[87]

Kashani AH, Uang J, Mert M, et al. Surgical method for implantation of a biosynthetic retinal pigment epithelium monolayer for geographic atrophy: experience from a phase 1/2a study. Ophthalmol Retina. 2020;4(3): 264-273.
DOI Google Scholar
[88]

Mandai M, Watanabe A, Kurimoto Y, et al. Autologous induced stem-cellderived retinal cells for macular degeneration. N Engl J Med. 2017;376(11): 1038-1046.
DOI Google Scholar
[89]

Takagi S, Mandai M, Gocho K, et al. Evaluation of transplanted autologous induced pluripotent stem cell-derived retinal pigment epithelium in exudative age-related macular degeneration. Ophthalmol Retina. 2019;3(10): 850-859.
DOI Google Scholar
[90]

Schweitzer JS, Song B, Herrington TM, et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson's disease. N Engl J Med. 2020;382(20): 1926-1932.
DOI Google Scholar
[91]

Sugai K, Sumida M, Shofuda T, et al. First-in-human clinical trial of transplantation of iPSC-derived NS/PCs in subacute complete spinal cord injury: study protocol. Regen Ther. 2021;18: 321-333.
DOI Google Scholar
[92]

Wang ZG, Luo Y, Chen LA, et al. Safety of neural stem cell transplantation in patients with severe traumatic brain injury. Exp Ther Med. 2017;13(6): 3613-3618.
DOI Google Scholar
[93]

Steinberg GK, Kondziolka D, Wechsler LR, et al. Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (SB623): a phase 1/2a study. J Neurosurg. 2018: 1-11.
DOI Google Scholar
[94]

Gupta N, Henry RG, Kang SM, et al. Long-term safety, immunologic response, and imaging outcomes following neural stem cell transplantation for pelizaeus-merzbacher disease. Stem Cell Rep. 2019;13(2): 254-261.
DOI Google Scholar
[95]

Levi AD, Okonkwo DO, Park P, et al. Emerging safety of intramedullary transplantation of human neural stem cells in chronic cervical and thoracic spinal cord injury. Neurosurgery. 2018;82(4): 562-575.
DOI Google Scholar
[96]

Nittala MG, Uji A, Velaga SB, et al. Effect of human central nervous system stem cell subretinal transplantation on progression of geographic atrophy secondary to nonneovascular age-related macular degeneration. Ophthalmol Retina. 2021;5(1): 32-40.
DOI Google Scholar
[97]

Muir KW, Bulters D, Willmot M, et al. Intracerebral implantation of human neural stem cells and motor recovery after stroke: multicentre prospective single-arm study (PISCES-2). J Neurol Neurosurg Psychiatry. 2020;91(4): 396-401.
DOI Google Scholar
[98]

Zhang GZ, Li Y, Reuss JL, et al. Stable intracerebral transplantation of neural stem cells for the treatment of paralysis due to ischemic stroke. Stem Cells Transl Med. 2019;8(10): 999-1007.
DOI Google Scholar
[99]

Curtis E, Martin JR, Gabel B, et al. A first-in-human, phase Ⅰ study of neural stem cell transplantation for chronic spinal cord injury. Cell Stem Cell. 2018;22(6): 941-950. e6.
DOI Google Scholar
[100]

Curt A, Hsieh J, Schubert M, et al. The damaged spinal cord is a suitable target for stem cell transplantation. Neurorehabilitation Neural Repair. 2020;34(8): 758-768.
DOI Google Scholar
[101]

Mazzini L, Gelati M, Profico DC, et al. Results from Phase Ⅰ clinical trial with intraspinal injection of neural stem cells in amyotrophic lateral sclerosis: a long-term outcome. Stem Cells Transl Med. 2019;8(9): 887-897.
DOI Google Scholar
[102]

Harris VK, Stark J, Vyshkina T, et al. Phase Ⅰ trial of intrathecal mesenchymal stem cell-derived neural progenitors in progressive multiple sclerosis. EBioMedicine. 2018;29: 23-30.
DOI Google Scholar
[103]

Ammar A, Osman Y, Hendam A, et al. A method for reconstruction of severely damaged spinal cord using autologous hematopoietic stem cells and plateletrich protein as a biological scaffold. Asian J Neurosurg. 2017;12(4): 681.
DOI Google Scholar
[104]

Savitz SI, Yavagal D, Rappard G, et al. A phase 2 randomized, sham-controlled trial of internal carotid artery infusion of autologous bone marrow-derived ALD-401 cells in patients with recent stable ischemic stroke (RECOVERstroke). Circulation. 2019;139(2): 192-205.
DOI Google Scholar
[105]

Hess DC, Wechsler LR, Clark WM, et al. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16(5): 360-368.
DOI Google Scholar
[106]

Fang J, Guo Y, Tan S, et al. Autologous endothelial progenitor cells transplantation for acute ischemic stroke: a 4-year follow-up study. Stem Cells Transl Med. 2019;8(1): 14-21.
DOI Google Scholar
[107]
SanBio Co. Ltd. SanBio and Sumitomo Dainippon Pharma announce topline results from a phase 2b study in the U.S. Evaluating SB623, a regenerative cell medicine for the treatment of patients with chronic stroke. https://www.sumitomo-pharma.com/ir/news/2019/20190129.html. Accessed March 12, 2022.
[108]

Jaillard A, Hommel M, Moisan A, et al. Autologous mesenchymal stem cells improve motor recovery in subacute ischemic stroke: a randomized clinical trial. Transl Stroke Res. 2020;11(5): 910-923.
DOI Google Scholar
[109]

Chung JW, Chang WH, Bang OY, et al. Efficacy and safety of intravenous mesenchymal stem cells for ischemic stroke. Neurology. 2021;96(7): e1012-e1023.
DOI Google Scholar
[110]

Law ZK, Tan HJ, Chin SP, et al. The effects of intravenous infusion of autologous mesenchymal stromal cells in patients with subacute middle cerebral artery infarct: a phase 2 randomized controlled trial on safety, tolerability and efficacy. Cytotherapy. 2021;23(9): 833-840.
DOI Google Scholar
[111]

Rah WJ, Lee YH, Moon JH, et al. Neuroregenerative potential of intravenous GCSF and autologous peripheral blood stem cells in children with cerebral palsy: a randomized, double-blind, cross-over study. J Transl Med. 2017;15(1): 16.
DOI Google Scholar
[112]

Sun JM, Song AW, Case LE, et al. Effect of autologous cord blood infusion on motor function and brain connectivity in young children with cerebral palsy: a randomized, placebo-controlled trial. Stem Cells Transl Med. 2017;6(12): 2071-2078.
DOI Google Scholar
[113]

Levi AD, Anderson KD, Okonkwo DO, et al. Clinical outcomes from a multicenter study of human neural stem cell transplantation in chronic cervical spinal cord injury. J Neurotrauma. 2019;36(6): 891-902.
DOI Google Scholar
[114]

Lublin FD, Bowen JD, Huddlestone J, et al. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebocontrolled, multiple-dose study. Mult Scler Relat Disord. 2014;3(6): 696-704.
DOI Google Scholar
[115]

Berry JD, Cudkowicz ME, Windebank AJ, et al. NurOwn, phase 2, randomized, clinical trial in patients with ALS. Neurology. 2019;93(24): e2294-e2305.
DOI Google Scholar
[116]

Kawabori M, Weintraub AH, Imai H, et al. Cell therapy for chronic TBI. Neurology. 2021;96(8): e1202-e1214.
DOI Google Scholar
[117]

Min K, Suh MR, Cho KH, et al. Potentiation of cord blood cell therapy with erythropoietin for children with CP: a 2 × 2 factorial randomized placebocontrolled trial. Stem Cell Res Ther. 2020;11(1): 509.
DOI Google Scholar
[118]

Amanat M, Majmaa A, Zarrabi M, et al. Clinical and imaging outcomes after intrathecal injection of umbilical cord tissue mesenchymal stem cells in cerebral palsy: a randomized double-blind sham-controlled clinical trial. Stem Cell Res Ther. 2021;12(1): 439.
DOI Google Scholar
[119]

Petrou P, Kassis I, Levin N, et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain. 2020;143(12): 3574-3588.
DOI Google Scholar
[120]

Petrou P, Kassis I, Ginzberg A, et al. Long-term clinical and immunological effects of repeated mesenchymal stem cell injections in patients with progressive forms of multiple sclerosis. Front Neurol. 2021;12: 639315.
DOI Google Scholar
[121]

Huang HY, Young W, Ziad A, et al. Beijing declaration of international association of neurorestoratology. J Neurorestoratol. 2015;3: 121.
DOI Google Scholar
[122]

Gobbel GT, Kondziolka D, Fellows-Mayle W, et al. Cellular transplantation for the nervous system: impact of time after preparation on cell viability and survival. J Neurosurg. 2010;113(3): 666-672.
DOI Google Scholar
[123]

Dominici M, le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4): 315-317.
DOI Google Scholar
[124]

Galipeau J, Krampera M, Barrett J, et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016;18(2): 151-159.
DOI Google Scholar
[125]

Kondziolka D, Wechsler L, Goldstein S, et al. Transplantation of cultured human neuronal cells for patients with stroke. Neurology. 2000;55(4): 565-569.
DOI Google Scholar
[126]

Nelson PT, Kondziolka D, Wechsler L, et al. Clonal human (hNT) neuron grafts for stroke therapy: neuropathology in a patient 27 months after implantation. Am J Pathol. 2002;160(4): 1201-1206.
DOI Google Scholar
[127]

Huang H, Chen L, Xi H, et al. Olfactory ensheathing cells transplantation for central nervous system diseases in 1,255 patients (in Chinese). Chin J Reparative Reconstr Surg. 2009;23(1): 14-20.
Google Scholar
[128]

Huang HY, Chen L, Wang HM, et al. Influence of patients' age on functional recovery after transplantation of olfactory ensheathing cells into injured spinal cord injury. Chin Med J (Engl). 2003;116(10): 1488-1491.
Google Scholar
[129]

Chen L, Huang HY, Xi HT, et al. A prospective randomized double-blind clinical trial using a combination of olfactory ensheathing cells and schwann cells for the treatment of chronic complete spinal cord injuries. Cell Transplant. 2014;23(1_suppl l): 35-44.
DOI Google Scholar
[130]

Syková E, Rychmach P, Drahorádová I, et al. Transplantation of mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: results of phase Ⅰ/Ⅱa clinical trial. Cell Transplant. 2017;26(4): 647-658.
DOI Google Scholar
[131]

Mehta T, Feroz A, Thakkar U, et al. Subarachnoid placement of stem cells in neurological disorders. Transplant Proc. 2008;40(4): 1145-1147.
DOI Google Scholar
[132]

Battistella V, de Freitas GR, da Fonseca LM, et al. Safety of autologous bone marrow mononuclear cell transplantation in patients with nonacute ischemic stroke. Regen Med. 2011;6(1): 45-52.
DOI Google Scholar
[133]

Friedrich MA, Martins MP, Araújo MD, et al. Intra-arterial infusion of autologous bone marrow mononuclear cells in patients with moderate to severe middle cerebral artery acute ischemic stroke. Cell Transplant. 2012;21(suppl 1): S13-S21.
DOI Google Scholar
[134]

Moviglia G, Viña RF, Brizuela J, et al. Combined protocol of cell therapy for chronic spinal cord injury. Report on the electrical and functional recovery of two patients. Cytotherapy. 2006;8(3): 202-209.
DOI Google Scholar
[135]

Lee JS, Hong JM, Moon GJ, et al. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cell. 2010;28(6): 1099-1106.
DOI Google Scholar
[136]

Konomi T, Suda K, Ozaki M, et al. Predictive factors for irreversible motor paralysis following cervical spinal cord injury. Spinal Cord. 2021;59(5): 554-562.
DOI Google Scholar
[137]

Huang HY, Chen L, Xi HT, et al. Fetal olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients: a controlled pilot study. Clin Transplant. 2008;22(6): 710-718.
DOI Google Scholar
[138]

Chen L, Huang HY, Xi HT, et al. Intracranial transplant of olfactory ensheathing cells in children and adolescents with cerebral palsy: a randomized controlled clinical trial. Cell Transplant. 2010;19(2): 185-192.
DOI Google Scholar
[139]

Huang HY, Young W, Skaper S, et al. Clinical neurorestorative therapeutic guidelines for spinal cord injury (IANR/CANR version 2019). J Orthop Transl. 2020;20: 14-24.
DOI Google Scholar
[140]

El Masri WS. Spontaneous neurological recovery of patients with acute traumatic spinal cord injuries (ATSCI) without intervention the injured cord. Int J Orthopedics Rehabil. 2021;8: 19-29.
DOI Google Scholar
[141]
Bryukhovetskiy. Tissue engineering of spinal cord injury in Neurorestoratology. In: Huang H, Raisman G, Sanberg PR, et al., eds. Neurorestoratology. New York: Nova Biomedical; 2015: 45-46; vol. 2.
[142]
Huang H, Raisman G, Sanberg PR, et al. Neurorestoratology.. vol. 2. New York: Nova Biomedical; 2015.
[143]

Huang H. CNS Neurorestoratology. Beijing, China: Science Press; 2009.
[144]

Siniscalco D, Sych N. Stem cell transplantation for nervous system disorders in Italy, European Union, and Ukraine: clinical approach and governmental policies. Transl Neurosci Clin. 2015;1(2): 125-127.
DOI Google Scholar
Publication history
Copyright
Rights and permissions

Publication history

Received: 12 March 2022
Revised: 21 May 2022
Accepted: 08 June 2022
Published: 30 July 2022
Issue date: September 2022

Copyright

© 2022 The Authors. Published by Elsevier Ltd on behalf of Tsinghua University Press.

Rights and permissions

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Return